Enhancing gastric cancer conventional chemotherapy effects by triple angiokinase inhibitor nintedanib in preclinical models
BackgroundGastric adenocarcinoma (GAC) is the fourth leading cause of cancer death worldwide. Systemic chemotherapy is a preferred treatment option for advanced and recurrent GAC, but response rates and survival prolongation remain limited. Tumor angiogenesis plays a critical role in GAC growth, inv...
Main Authors: | Niranjan Awasthi, Margaret A. Schwarz, Quinn Kaurich, Changhua Zhang, Frank Hilberg, Roderich E. Schwarz |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-05-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1145999/full |
Similar Items
-
Proteomic study on nintedanib in gastric cancer cells
by: Xiaohua Dong, et al.
Published: (2024-02-01) -
Nintedanib treatment for bleomycin-induced lung injury - First report
by: Dina Rnjak, et al.
Published: (2023-01-01) -
Nintedanib antiangiogenic inhibitor effectiveness in delaying adenocarcinoma progression in Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP)
by: Raquel Frenedoso da Silva, et al.
Published: (2017-05-01) -
Role of Nintedanib in COVID-19-Related Lung Fibrosis
by: Alif Fathurrachman, et al.
Published: (2022-09-01) -
Clinical significance of high monocyte counts for the continuous treatment with nintedanib
by: Shingo Tsuneyoshi, et al.
Published: (2023-07-01)